Treatment News : Might Aspirin Reduce Cardiovascular Risk in People With HIV? - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » August 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 20, 2012

Might Aspirin Reduce Cardiovascular Risk in People With HIV?

by Tim Horn

AIDS 2012Could daily aspirin help reduce the excessive risk of a heart attack and other health complications associated with blood clots, immune activation and inflammation in people living with HIV? A small pilot study reported Thursday, July 26, at the XIX International AIDS Conference in Washington, DC, by New York University (NYU) researchers points to the possibility.

Aspirin’s effect on heart health is well understood. Most heart attacks begin when a cholesterol plaque causes the wall of an artery to tear, which results in platelets rushing to the area so they can clot the blood. If too many platelets accumulate, the tiny cells can block the blood vessel and cut off oxygen needed to keep the heart working properly.

Aspirin—even at very low doses—can inhibit this platelet formation. It may also help minimize the immune activation and inflammation that can lead to the weakening of blood vessel walls in response to cholesterol plaque buildup, potentially reducing the risk of artery ruptures.

In light of its low risk and low cost—compounded by the fact that it has been shown to reduce the risk of life-threatening heart attacks in HIV-negative individuals with cardiovascular disease—Meagan O’Brien, MD, of NYU and her colleagues set out to evaluate the effects of aspirin in 25 people living with HIV, all of whom were receiving antiretroviral therapy. They took a low dose of the over-the-counter drug (81 milligrams) for a week and were compared with 44 HIV-negative controls.

The researchers showed that aspirin affected patients’ platelet aggregation—the tendency to clump together in the blood.

Before aspirin was given in the study, platelet aggregation was 7.5 percent higher among those living with HIV compared with control patients. “HIV-infected subjects on antiretroviral therapy have hyper-reactive platelets,” O’Brien said.

During the study, the researchers collected blood samples from the volunteers and used two chemicals—adenosine diphosphate (ADP) and arachidonic acid (AA)—to encourage platelets to clump. Before aspirin was administered, platelet aggregation averaged 59.3 percent in response to ADP and 54.9 percent in response to AA in the HIV-positive study subjects. After one day of aspirin, aggregation in response to ADP and AA decreased to 32.2 percent and 9.1 percent, respectively. After one week of aspirin therapy, platelet aggregation decreased to 28.4 percent in samples exposed to ADP. In samples exposed to AA, platelet aggregation among the HIV-positive volunteers remained below 10 percent, but it was still significantly higher than the aggregation result seen in the 44 study volunteers not infected with HIV.

O’Brien and her colleagues also found that daily aspirin decreased markers of immune activation and three important markers of inflammation: C-reactive protein (CRP), interleukin-6 (IL-6) and D-dimer. Though the decreases in CD4 and CD8 cell activation were statistically significant, the decreases in CRP, IL-6 and D-dimer were not.

Though the study was too short and too small to determine if aspirin reduced the risk of heart attacks or other inflammation-related health problems—including cancer—the data are encouraging. Additional research, including large placebo-controlled clinical trials, will be needed to determine whether the benefits of low-dose aspirin therapy outweigh its potential risks—gastrointestinal bleeding is a risk associated with chronic aspirin therapy—in people living with HIV.

Search: aspirin, cardiovascular disease, cvd, myocardial infarction, heart attack, platelets, inflammation, immun activation, aids 2012

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 1 (of 1 total)    

Dylan, North Wales, UK, 2012-08-24 06:21:18
Started taking a little aspirin once a day, about six months ago, and have noted a lessening of my overactive brain while asleep. Why should that be? Inflammation of internal organs in HIV+ people is known, and maybe that inflammation extends to the brain? If so, perhaps the aspirin has reduced inflammation in my brain and that has had the effect of calming my mental activity down at night while sleeping . . . finally allowing me to get a reasonable night's sleep. An unintended benefit.

comments 1 - 1 (of 1 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.